MIRTAZAPINE
Excessive Daytime Sleepiness
University Health Network, TorontoSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Excessive Daytime Sleepiness cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pitolisant Bioprojet | Phase 3 | BBB |
Modafinil Bioprojet | Phase 3 | BB |
bf2.649 Bioprojet | Phase 2 | B |
Ben-2001 BenevolentAI Bio | Phase 2 | B |
Same molecule, other indications
MIRTAZAPINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →